Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naloxone controlled release - Algobate

Next Previous
Drug Profile

Naloxone controlled release - Algobate

Alternative Names: Naloxone extended release; Naloxone prolonged release; NLX PRT; NLX-PR

Latest Information Update: 29 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algobate AG; Develco Pharma Schweiz
  • Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Constipation

Highest Development Phases

  • Phase III Constipation

Most Recent Events

  • 28 Nov 2022 No development reported - Phase-III for Constipation in Portugal (PO) (NCT03687268)
  • 27 Oct 2020 No development reported - Phase-III for Constipation in Bulgaria, Serbia, Poland (PO) (NCT03687268)
  • 02 May 2020 Develco Pharma Schweiz completes the phase III NAXOS trial in Constipation in Czech Republic, Germany, Hungary, Poland, Portugal, Slovakia, Spain and the UK (PO) (EudraCT2017-000657-39)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top